The association between fibrotic diseases and treatment resistant hypertension in England.

IF 8.4 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
G M Massen, P W Stone, R G Jenkins, R J Allen, L V Wain, I Stewart, U Tayal, J K Quint
{"title":"The association between fibrotic diseases and treatment resistant hypertension in England.","authors":"G M Massen, P W Stone, R G Jenkins, R J Allen, L V Wain, I Stewart, U Tayal, J K Quint","doi":"10.1093/eurjpc/zwaf068","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Multimorbidity has been identified as a research priority in recent years, fibrosis (progressive organ scarring) is one mechanism which may underpin multimorbidity. Some studies suggest hypertension could be fibrotic, particularly severe hypertension (uncontrollable with medications), however it is not currently known whether severe hypertension is associated with fibrotic conditions.</p><p><strong>Objective: </strong>To investigate whether treatment resistant hypertension is associated with fibrotic conditions.</p><p><strong>Methods: </strong>We used the Clinical Practice Research Datalink (CPRD) Aurum primary care database to define a cohort of people with hypertension during 2015. We determined the percentage of people who had conditions with fibrotic manifestations and explored differences respective to hypertension control. We applied multivariable logistic regression to analyse associations (p<0.001) between hypertension control and each fibrotic condition respectively.</p><p><strong>Results: </strong>Of 1,340,495 people with hypertension during 2015, 83.50% (n=1,119,333) had managed hypertension either by lifestyle or medication; 16.50% (n=221,162) had treatment resistant hypertension. Fibrotic conditions were more common ((75.40% (95%CI: 75.20-75.60) vs. 68.90% (95%CI: 68.81-70.01)) in people with treatment resistant hypertension compared with those with managed hypertension. We found that treatment resistant hypertension was associated with; cardiomyopathy (ORadj:1.85, 95%CI:1.81-1.90), both type 1 and type 2 diabetes (ORadj:1.49,95%CI:1.44-1.55, ORadj:1.61,95%CI:1.60-1.63, respectively), liver fibrosis (ORadj:1.52, 95%CI: 1.46-1.58), valve fibrosis (ORadj:1.41, 95%CI:1.37-1.44) and urinary fibrosis (ORadj:1.41,95%CI:1.36-1.47).</p><p><strong>Conclusion: </strong>The proportion of people with fibrotic conditions was greater in those with treatment resistant hypertension than managed hypertension. The identified associations between treatment resistant hypertension and fibrotic conditions may point to common disease pathways which should be further explored to understand shared mechanisms.</p>","PeriodicalId":12051,"journal":{"name":"European journal of preventive cardiology","volume":" ","pages":""},"PeriodicalIF":8.4000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of preventive cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/eurjpc/zwaf068","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Multimorbidity has been identified as a research priority in recent years, fibrosis (progressive organ scarring) is one mechanism which may underpin multimorbidity. Some studies suggest hypertension could be fibrotic, particularly severe hypertension (uncontrollable with medications), however it is not currently known whether severe hypertension is associated with fibrotic conditions.

Objective: To investigate whether treatment resistant hypertension is associated with fibrotic conditions.

Methods: We used the Clinical Practice Research Datalink (CPRD) Aurum primary care database to define a cohort of people with hypertension during 2015. We determined the percentage of people who had conditions with fibrotic manifestations and explored differences respective to hypertension control. We applied multivariable logistic regression to analyse associations (p<0.001) between hypertension control and each fibrotic condition respectively.

Results: Of 1,340,495 people with hypertension during 2015, 83.50% (n=1,119,333) had managed hypertension either by lifestyle or medication; 16.50% (n=221,162) had treatment resistant hypertension. Fibrotic conditions were more common ((75.40% (95%CI: 75.20-75.60) vs. 68.90% (95%CI: 68.81-70.01)) in people with treatment resistant hypertension compared with those with managed hypertension. We found that treatment resistant hypertension was associated with; cardiomyopathy (ORadj:1.85, 95%CI:1.81-1.90), both type 1 and type 2 diabetes (ORadj:1.49,95%CI:1.44-1.55, ORadj:1.61,95%CI:1.60-1.63, respectively), liver fibrosis (ORadj:1.52, 95%CI: 1.46-1.58), valve fibrosis (ORadj:1.41, 95%CI:1.37-1.44) and urinary fibrosis (ORadj:1.41,95%CI:1.36-1.47).

Conclusion: The proportion of people with fibrotic conditions was greater in those with treatment resistant hypertension than managed hypertension. The identified associations between treatment resistant hypertension and fibrotic conditions may point to common disease pathways which should be further explored to understand shared mechanisms.

求助全文
约1分钟内获得全文 求助全文
来源期刊
European journal of preventive cardiology
European journal of preventive cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
12.50
自引率
12.00%
发文量
601
审稿时长
3-8 weeks
期刊介绍: European Journal of Preventive Cardiology (EJPC) is an official journal of the European Society of Cardiology (ESC) and the European Association of Preventive Cardiology (EAPC). The journal covers a wide range of scientific, clinical, and public health disciplines related to cardiovascular disease prevention, risk factor management, cardiovascular rehabilitation, population science and public health, and exercise physiology. The categories covered by the journal include classical risk factors and treatment, lifestyle risk factors, non-modifiable cardiovascular risk factors, cardiovascular conditions, concomitant pathological conditions, sport cardiology, diagnostic tests, care settings, epidemiology, pharmacology and pharmacotherapy, machine learning, and artificial intelligence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信